Skip to content
  |  Print Print this page  |  Text Size Reduce font size  Increase font size

Email Discussions

Email discussion disclaimer

Please note that all information and policies are only current at the time the response is sent and individual hospitals should be contacted to ascertain current policies and practices. The responses received are only representative of the hospitals participating in the discussion at the time and do not necessarily indicate a complete picture of current practices.

Information sharing occurs on the understanding that due acknowledgement will be given to the original source and that the information will not be quoted or used out of the context of the discussion. Permission should be sought from the original source before any policy, protocol or guideline is used or applied in another setting.

2017

May

  • Removal of HYDROmorphone 50mg/5mL and upcoming availability of HYDROmorphone 50mg/mL
    PDF ~ 264 KB

April

March

  • Perioperative management plan for patients taking regular anticoagulant or antiplatelet agents
    PDF ~ 201 KB

January

  • Off-label use of rituximab in membranous nephropathy
    PDF ~ 283 KB

Archived discussions:

Please contact the office if you require older discussions.